Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 4530628)

Published in J Natl Compr Canc Netw on June 01, 2013

Authors

Damon Reed1, Ragini Kudchadkar, Jonathan S Zager, Vernon K Sondak, Jane L Messina

Author Affiliations

1: Department of a Sarcoma Oncology, Moffitt Cancer Center, Tampa, Florida 33612, USA. Damon.Reed@moffitt.org

Articles cited by this

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet (2012) 15.74

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62

The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol (2010) 3.02

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2010) 2.56

Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol (1999) 2.50

Melanoma in children. N Engl J Med (1995) 2.35

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28

Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet (2010) 2.14

Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines. Eur Respir J (2011) 2.13

The approach to the patient with a difficult melanocytic lesion. Pathology (2004) 2.12

Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol (2003) 2.05

Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02

Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00

Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics (2005) 1.99

Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol (2009) 1.87

The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. Cancer (2009) 1.85

Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol (2011) 1.75

Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma. Am J Clin Pathol (2004) 1.59

Incidence of childhood and adolescent melanoma in the United States: 1973-2009. Pediatrics (2013) 1.52

Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol (2010) 1.43

High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr Blood Cancer (2005) 1.43

Melanoma and melanocytic tumors of uncertain malignant potential in children, adolescents and young adults--the Stanford experience 1995-2008. Pediatr Dermatol (2010) 1.40

Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations. J Pediatr (1992) 1.39

Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol (2007) 1.37

Melanoma. J Natl Compr Canc Netw (2009) 1.37

Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol (2008) 1.07

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol (2001) 1.04

Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol (2010) 1.02

Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol (2009) 1.01

Pediatric melanoma: a review. Cancer Control (2009) 1.00

Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg (2005) 0.97

Agreement of dermatopathologists in the evaluation of clinically difficult melanocytic lesions: how golden is the 'gold standard'? Dermatology (2012) 0.97

High-resolution array-based comparative genomic hybridization for distinguishing paraffin-embedded Spitz nevi and melanomas. Diagn Mol Pathol (2004) 0.96

Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology (2009) 0.94

Melanoma in children. Arch Pathol Lab Med (2011) 0.91

The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol (2012) 0.91

Trends in pediatric melanoma mortality in the United States, 1968 through 2004. Dermatol Surg (2007) 0.90

Melanoma. J Natl Compr Canc Netw (2012) 0.90

Metastatic malignant melanoma in prepubertal children. Pediatrics (1975) 0.90

Update on fluorescence in situ hybridization in melanoma: state of the art. Arch Pathol Lab Med (2011) 0.89

PET CT imaging in patients undergoing sentinel node biopsy for melanoma. Eur J Surg Oncol (2007) 0.89

Pediatric melanoma: a single-institution experience of 150 patients. J Pediatr Surg (2009) 0.89

Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res (2004) 0.88

p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi. J Am Acad Dermatol (2011) 0.87

Correlating array comparative genomic hybridization findings with histology and outcome in spitzoid melanocytic neoplasms. Int J Clin Exp Pathol (2010) 0.87

Sentinel lymph node biopsy in pediatric and adolescent cutaneous melanoma patients. Ann Surg Oncol (2009) 0.86

Spitz nevi, atypical spitzoid neoplasms, and spitzoid melanoma. Clin Lab Med (2011) 0.86

Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. Mod Pathol (2005) 0.85

Correlation between histologic assessment and fluorescence in situ hybridization using MelanoSITE in evaluation of histologically ambiguous melanocytic lesions. Arch Pathol Lab Med (2012) 0.84

Excised melanocytic lesions in children and adolescents - a 10-year survey. Br J Dermatol (2012) 0.83

Value of ultrasonography compared with physical examination for the detection of locoregional metastases in patients with cutaneous melanoma. Melanoma Res (2003) 0.83

Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors. Hum Pathol (2012) 0.83

Pediatric melanoma: are recent advances in the management of adult melanoma relevant to the pediatric population. J Pediatr Hematol Oncol (2000) 0.83

The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma. Cancer (2005) 0.83

Comparison of the use and results of sentinel lymph node biopsy in children and young adults with melanoma. Cancer (2011) 0.81

Pediatric "STUMP" lesions: evaluation and management of difficult atypical Spitzoid lesions in children. J Am Acad Dermatol (2011) 0.79

Unanswered questions about margin recommendations for primary cutaneous melanoma. J Natl Compr Canc Netw (2012) 0.79

Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. J Cutan Pathol (2012) 0.78

Comparative genomic hybridization for the diagnosis of melanoma. Eur J Plast Surg (2009) 0.77

Outcomes in pediatric atypical spitz tumors treated without sentinel lymph node biopsy. Pediatr Dermatol (2011) 0.76

FISH analysis for diagnostic evaluation of challenging melanocytic lesions. Histol Histopathol (2010) 0.76

Articles by these authors

Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80

Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest (2004) 4.27

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol (2002) 3.05

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88

Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol (2010) 2.83

The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res (2012) 2.31

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30

Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer (2003) 2.23

The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol (2005) 2.12

Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol (2008) 2.11

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (2008) 2.09

Chemotherapy for metastatic melanoma: time for a change? Cancer (2007) 1.99

Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92

12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 1.81

Primary mucosal melanoma. J Am Acad Dermatol (2007) 1.80

Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother (2012) 1.68

A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer (2011) 1.66

The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer (2007) 1.64

Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol (2008) 1.61

Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol (2002) 1.57

Multimodality management of desmoid tumors: how important is a negative surgical margin? J Surg Oncol (2008) 1.55

Interferon alfa-2a for melanoma metastases. Lancet (2002) 1.55

Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer (2004) 1.50

Melanoma--an unlikely poster child for personalized cancer therapy. N Engl J Med (2010) 1.47

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46

Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist (2003) 1.42

Proper margins of excision in dermatofibrosarcoma protuberans: wide or narrow? Ann Surg Oncol (2008) 1.42

Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res (2008) 1.41

A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg (2009) 1.39

Lymphangiogenesis: host and tumor factors in nodal metastasis. Arch Dermatol (2008) 1.38

Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol (2011) 1.35

Lymphatic mapping and sentinel lymph node biopsy in the detection of early metastasis from sweat gland carcinoma. Cancer (2003) 1.35

Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol (2010) 1.35

CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surg Oncol (2008) 1.28

Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J (2004) 1.24

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer (2003) 1.24

Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer (2013) 1.23

Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest (2003) 1.23

Ipilimumab. Nat Rev Drug Discov (2011) 1.20

Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys (2011) 1.17

Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. Cancer Control (2009) 1.15

Cutaneous melanoma: prognostic factors. Cancer Control (2005) 1.13

New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res (2011) 1.12

Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol (2012) 1.11

Conjunctival melanomas harbor BRAF and NRAS mutations--Letter. Clin Cancer Res (2013) 1.10

Retroperitoneal sarcomas. Cancer Imaging (2005) 1.09

Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol (2013) 1.09

c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol (2009) 1.08

Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol (2011) 1.07

Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys (2007) 1.07

Point: Interferon-alpha for adjuvant therapy for melanoma patients. J Natl Compr Canc Netw (2004) 1.06

Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery (2002) 1.04

Generation of a tumor spheroid in a microgravity environment as a 3D model of melanoma. In Vitro Cell Dev Biol Anim (2009) 1.04

Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev (2012) 1.04

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res (2012) 1.04

Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer (2003) 1.03

Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol (2009) 1.03

Treatment options for limited or symptomatic metastatic melanoma. Cancer Control (2008) 1.03

Current diagnosis and management of retroperitoneal sarcoma. Cancer Control (2011) 1.03

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer (2010) 1.02

Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol (2010) 1.02

Case-control study of Merkel cell polyomavirus infection and cutaneous squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2011) 1.02

Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer (2002) 1.02

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res (2009) 1.02

Markers and tissue resources for melanoma: meeting report. Cancer Res (2006) 1.01

Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res (2008) 1.01

Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control (2008) 1.01

Cutaneous protothecosis: a case report and review of the literature. Cutis (2007) 1.00